Su X - Search Results

1

Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.

Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H. Jin S, et al. Among authors: su c, su x. Int J Cancer. 2023 Apr 15;152(8):1648-1658. doi: 10.1002/ijc.34372. Epub 2022 Dec 1. Int J Cancer. 2023. PMID: 36444498 Free article. Clinical Trial.

2

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.

Xia P, Zhang L, Li P, Liu E, Li W, Zhang J, Li H, Su X, Jiang G. Xia P, et al. Among authors: su x. J Transl Med. 2021 Jul 16;19(1):308. doi: 10.1186/s12967-021-02982-4. J Transl Med. 2021. PMID: 34271921 Free PMC article.

3

Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: su x. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.

4

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer.

Wang X, Liu Y, Meng Z, Wu Y, Wang S, Jin G, Qin Y, Wang F, Wang J, Zhou H, Su X, Fu X, Wang X, Shi X, Wen Z, Jia X, Qin Q, Gao Y, Guo W, Lu S. Wang X, et al. Among authors: su x. Ann Transl Med. 2021 Apr;9(8):635. doi: 10.21037/atm-20-7155. Ann Transl Med. 2021. PMID: 33987333 Free PMC article.

5

Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung.

Xie L, Cai Z, Lu H, Meng F, Zhang X, Luo K, Su X, Lei Y, Xu J, Lou J, Wang H, Du Z, Wang Y, Li Y, Ren T, Xu J, Sun X, Tang X, Guo W. Xie L, et al. Among authors: su x. Heliyon. 2023 Apr 17;9(5):e15527. doi: 10.1016/j.heliyon.2023.e15527. eCollection 2023 May. Heliyon. 2023. PMID: 37205995 Free PMC article.

6

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.

Nie X, Zhang P, Bie Z, Song C, Zhang M, Ma D, Cui D, Cheng G, Li H, Lei Y, Su X, Wu W, Li L. Nie X, et al. Among authors: su x. World J Surg Oncol. 2023 Aug 16;21(1):246. doi: 10.1186/s12957-023-03129-z. World J Surg Oncol. 2023. PMID: 37587479 Free PMC article.

7

Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion.

Zhang X, Feng J, Su X, Lei Y, Wu W, Cheng X. Zhang X, et al. Among authors: su x. Onco Targets Ther. 2020 Dec 9;13:12667-12671. doi: 10.2147/OTT.S283617. eCollection 2020. Onco Targets Ther. 2020. PMID: 33328738 Free PMC article.

8

Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.

Lin Y, Lei Y, Li L, Su X, Tian Q, Wu W. Lin Y, et al. Among authors: su x. Onco Targets Ther. 2022 Jul 28;15:831-836. doi: 10.2147/OTT.S372134. eCollection 2022. Onco Targets Ther. 2022. PMID: 35923471 Free PMC article.

9

Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment.

Lin Y, Cheng L, Liu Y, Wang Y, Wang Q, Wang HL, Shi G, Li JS, Wang QN, Yang QM, Chen S, Su XL, Yang Y, Jiang M, Hu X, Fan P, Fang C, Zhou ZG, Dai L, Deng HX. Lin Y, et al. Among authors: su xl. Mucosal Immunol. 2021 Jan;14(1):187-198. doi: 10.1038/s41385-020-0297-3. Epub 2020 May 28. Mucosal Immunol. 2021. PMID: 32467604 Free article.

10

Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: su x. Nat Med. 2020 Jul;26(7):1149. doi: 10.1038/s41591-020-0973-6. Nat Med. 2020. PMID: 32555427

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,658 results

Search Page